MEDIPOST has started strengthening of global marketing and partnerships of cartilage regenerating stem cell treatment drug ‘CARTISTEM®’ by participating in regeneration medical field international academic conferences one after the other.
MEDIPOST has received much attention from European medical personnel at ‘2013 ICRS: International Cartilage Repair Society in Bologna, Italy over 6-7 December.
In this event, MEDIPOST presented domestic administration of ‘CARTISTEM®’ the world’s first stem cell treatment drug of its kind, clinical status in US and global marketing strategy.
Moreover, by installing academic booth at the event venue, they held 1:1 meetings with medical personnel and related company personnel of Europe and North America and discussed partnerships such as overseas joint development of ‘CARTISTEM®’
‘ICRS’ is one of the most prestigious academic conferences in the world in cartilage regeneration field, designating the International Standard Criteria regarding the extent of loss of cartilage (ICRS grade), and in the recent event more than 100 famous bio companies, hospitals and research centers participated.
On the other hand, before this event, MEDIPOST announced the clinical status of ‘CARTISTEM®’ at the ‘Stem Cells on the Mesa’ held in San Diego, USA in October, and in November also participated in ‘World Alliance Forum’ and ‘Commercial Translation of Regenerative Medicine’ held in San Francisco, USA and London, UK, respectively.
